S

Stoke Therapeutics

113 employees

Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Health Care
Therapeutics
Pharmaceutical

Date founded

2017

Funding rounds raised

Total raised

$90M

from 7 investors over 7 rounds

S

Stoke Therapeutics raised $90M on October 23, 2018

Investors: RA Capital Management, L.P., Sphera Fund, Perceptive Advisors, ATP (Apple Tree Partners), Redmile Group and RTW Investments, LP

S

Stoke Therapeutics raised $40M on January 4, 2018

Investors: ATP (Apple Tree Partners)

FAQ